Human Albumin is a protein naturally found in blood plasma. In this trial, it is administered as a medical product to patients after liver transplantation. This protein helps maintain proper fluid balance in the blood vessels and is essential for transporting various substances throughout the body. The treatment aims to maintain adequate albumin levels in the blood to protect kidney function after liver transplant surgery.

Acute Kidney Injury (AKI) – A sudden decrease in kidney function that develops within a few hours or days. The condition affects the kidneys’ ability to filter waste products from the blood, maintain fluid balance, and regulate various body functions. AKI can cause swelling in various parts of the body, decreased urine output, and changes in blood chemistry. The condition can develop due to various causes, including reduced blood flow to the kidneys, direct kidney damage, or blockage in the urinary tract.

Liver Transplantation Complications – A condition that occurs after receiving a new liver, where the body needs to adapt to the transplanted organ. During this period, various changes occur in the body’s systems, including fluid balance, blood circulation, and immune response. The body undergoes significant physiological adjustments as it works to accept and function with the new liver.

Early Graft Dysfunction – A condition that can develop shortly after liver transplantation where the new liver shows signs of poor function. The transplanted liver may struggle to perform its normal functions of protein synthesis, toxin removal, and bile production. This condition typically manifests in the first few days after transplantation.

Tacrolimus-induced Neurotoxicity – A condition that can develop in transplant patients taking tacrolimus medication, affecting the nervous system. It can cause various neurological symptoms, including tremors, headaches, and changes in mental status. The condition is related to the body’s response to immunosuppressive medication.